Todas las categorías
| Product Name | Descripción | Action |
|---|---|---|
| Amivantamab,Rybrevant,EGFR, cMet (MET), JNJ-61186372,anticuerpo bispecífico EGFR/c-MET,bispecífico IgG1 totalmente humano,inmunoterapia oncológica / NSCLC biológica,número CAS 2171511-58-1 | Trade Name : Rybrevant Target : EGFR, cMet (MET) Molecular Type : Bispecific Antibody Sales in 2025 (Millions of USD) : 179(First half of the year) All detailed product information shall be subject to the issued final COA. Should you need further in-depth documentation for this item, kindly get in ... |
|
| Polatuzumab vedotin,Polivy,CD79B,RG7596,ADC,terapia dirigida a CD79b,inhibidor de microtúbulos,ADC de oncología / DLBCL ADC / ADC de linfoma,infusión intravenosa,no CAS 1313206-42-6 | Trade Name : Polivy Target : CD79B Molecular Type : ADC Sales in 2025 (Millions of USD) : 850(First half of the year) All detailed product information shall be subject to the issued final COA. Should you need further in-depth documentation for this item, kindly get in touch with us. |
|
| Obinutuzumab, Gazyva, CD20, GA101, Nº CAS 949142-50-1, Anticuerpo monoclonal anti-CD20 (Tipo II), Anticuerpo IgG1 humanizado y glicoinmunizado, Biológico oncológico / Biológico para LLC / Biológico para linfoma folicular | Trade Name : Gazyva Target : CD20 Molecular Type : Monoclonal Antibody Sales in 2025 (Millions of USD) : 784(First three quarters) All detailed product information shall be subject to the issued final COA. Should you need further in-depth documentation for this item, kindly get in touch with us. |
|
| Ivonescimab, YIDAFANG® (Nombres comerciales aprobados para su uso en China), AK112, anticuerpo biespecífico PD-1/VEGF, Inmunoterapia oncológica / Terapia antiangiogénica, Anticuerpo biespecífico PD-1/VEGF, N.º CAS 2428381-53-5 | Trade Name : YIDAFANG® (Trade names approved for use in China) Target : N/A Molecular Type : PD-1/VEGF Bispecific antibody Sales in 2025 (Millions of USD) : 28(In 2024) All detailed product information shall be subject to the issued final COA. Should you need further in-depth documentation for this ... |
|
| Datopotamab deruxtecan-dlnk | Trade Name : Datroway Target : TROP-2 Molecular Type : ADC Sales in 2025 (Millions of USD) : 10(First Quarter) All detailed product information shall be subject to the issued final COA. Should you need further in-depth documentation for this item, kindly get in touch with us. |
|
| Tenecteplasa, Metalyse, Fibrina, TNK-tPA, Enzima trombolítica/fibrinolítica, tPA de tercera generación, Proteína recombinante, N.º CAS 191588-94-0 | Trade Name : Metalyse Target : Fibrin Molecular Type : Recombinant Protein Sales in 2025 (Millions of USD) : 1780(estimate) All detailed product information shall be subject to the issued final COA. Should you need further in-depth documentation for this item, kindly get in touch with us. |
|
| Tarlatamab, Imdelltra, DLL3&CD3, AMG 757, Inmunoterapia oncológica / Biológico SCLC, Infusión intravenosa, Citotoxicidad mediada por células T, Engancho bispecífico de células T, N.º CAS 2307488-83-9 | Trade Name : Imdelltra Target : DLL3&CD3 Molecular Type : Bispecific T-cell Engager Sales in 2025 (Millions of USD) : 215(First half of the year) All detailed product information shall be subject to the issued final COA. Should you need further in-depth documentation for this item, kindly get in ... |
|
| Serplulimab, HANSIZHUANG, PD-1, Hetronifly, HLX10, inhibidor de punto de control inmunitario anti-PD-1, anticuerpo monoclonal IgG4 humanizado, anticuerpo monoclonal, N.º CAS 2231029-82-4 | Trade Name : HANSIZHUANG Target : PD-1 Molecular Type : Monoclonal Antibody Sales in 2025 (Millions of USD) : 82(First half of the year) All detailed product information shall be subject to the issued final COA. Should you need further in-depth documentation for this item, kindly get in touch with ... |
